If you had backed AVITA Medical at the very start of 2026, the result would look dramatic on any brokerage screen. Holding AVITA Medical from the start of the year would have returned 393.4%, including dividends. That kind of move invites a hard look at what early shareholders were really judging. If the Medicare reimbursement dispute, trauma expansion push and cost cuts were all still unresolved on 2026-01-01, which of those uncertainties would you have leaned into and which would you have...
Motley Fool Press Release.
AVITA Medical Inc (AVHHL) posted $26.1 million in Q3 revenue with 84% gross margins, lifted its 2026 outlook to $92-$94 million, and expects to reach cash flow breakeven in Q4.
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 6, 2026, at 8:30 a.m.
On Thursday, AVITA Medical (NASDAQ:RCEL) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts
AVITA Medical’s updated valuation work now points to a fair value of $12.29, compared with the prior $11.06, which gives you a fresh reference point for where analysts see the stock’s central value today. The shift lines up with commentary that has turned more constructive after the PermeaDerm I data, recent quarterly results, and a view that current evidence and reimbursement trends support a higher fair valuation range. Read on to see what is driving this evolving narrative and how to track...
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences: Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference – Thursday, September 10, 2026 | Investor meetings with Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...
RCEL outlook: more predictable RECELL reimbursement, RECELL GO rollout, PermeaDerm economics, and Q4 2026 breakeven target.
This is the newest page. Registered accounts read further back.